Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
US Army
Fuji
Cerilliant
Chubb
Dow
Deloitte
UBS
Daiichi Sankyo

Generated: May 26, 2018

DrugPatentWatch Database Preview

PROHANCE Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Prohance, and what generic alternatives are available?

Prohance is a drug marketed by Bracco and is included in two NDAs.

The generic ingredient in PROHANCE is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.
Drug patent expirations by year for PROHANCE
Pharmacology for PROHANCE
Synonyms for PROHANCE
(+-)-(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium
(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium
[2,2',2''-{10-[2-(hydroxy-kappaO)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl-kappa(4)N(1),N(4),N(7),N(10)}triacetato-kappaO(3-)]gadolinium
066G548
1,4,7,10-Tetraazacyclododecan-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-, gadolinium complex
120066-54-8
AC1L1TS2
BC678010
CAS-120066-54-8
CCG-213206
CHEBI:31643
D01137
D0M1PL
DB00597
DO1137
DPNNNPAKRZOSMO-UHFFFAOYSA-K
DSSTox_CID_28588
DSSTox_GSID_48662
DSSTox_RID_82859
DTXSID2048662
gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate
Gadolinium-HP-D03A
Gadolinium-HP-Do 3A
Gadolinium-HP-DO3A
Gadolinium, (10-(2-(hydroxy-kappaO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kappaN1,kappaN4,kappaN7,kappaN10,kappaO1,kappaO4,kappaO7)-
Gadolinium, (10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-N(sup 1),N(sup 4),N(sup 7),N(sup 10),O(sup 1),O(sup 4),O(sup 7),O(sup 10))-
gadolinium(3+) 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
gadolinium(3+); 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
GADOTERIDOL
Gadoteridol (JAN/USP/INN)
Gadoteridol [USAN:INN:BAN:JAN]
Gadoteridolum
Gadoteridolum [INN-Latin]
GD-HP-DO 3A
Gd-HP-DO3A
Gd-HPDO3A
Gd(HP-DO3A)
HE300932
HMS3264D11
HSDB 7549
HY-B0933
LS-70971
MOLI001032
NCGC00182068-02
NCGC00182068-03
NCGC00182068-04
NSC-760055
NSC760055
Pharmakon1600-01503834
Prohance (TN)
Prohance Multipack
SCHEMBL1650466
SQ 32692
SQ-32692
Tox21_113025
Tox21_113025_1
Tox21_113128

US Patents and Regulatory Information for PROHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for PROHANCE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Sign Up ➤ Sign Up
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Sign Up ➤ Sign Up
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Sign Up ➤ Sign Up
Bracco PROHANCE gadoteridol INJECTABLE;INJECTION 020131-001 Nov 16, 1992 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Julphar
Farmers Insurance
UBS
Colorcon
McKinsey
Accenture
Moodys
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.